Literature DB >> 35978185

Is MDCT an accurate tool to differentiate between benign and malignant etiology in diffuse peritoneal disease?

Shyjumon George1, Kirthi Sathyakumar1, Mandeep Singh Bindra2, Anu Eapen3.   

Abstract

PURPOSE: There is often considerable overlap of imaging findings in benign and malignant peritoneal diseases. We evaluated patients with diffuse peritoneal disease, to assess the diagnostic value of MDCT in predicting benign or malignant etiology in patients with unknown etiology, by analyzing the various patterns of involvement, particularly tuberculosis (TB) vs malignancy.
METHODS: One hundred and thirty-six patients with diffuse peritoneal disease who had abdominal CT and subsequently underwent omental biopsies were included in the study. Peritoneal, mesenteric and omental involvement by disease was evaluated on CT using specific parameters. The presence of lymphadenopathy, ascites, scalloping of organs, involvement of liver and spleen, were also compared between benign and malignant conditions using histopathology as the gold standard.
RESULTS: In 136 patients, 72 benign and 64 malignant pathologies were classified as per histopathology. Higher age (p < 0.001), increasing omental thickness (mean 25.2 mm, p = 0.004), omental caking (p < 0.001), > 10 mm mesenteric/peritoneal nodules (p < 0.03), visceral scalloping (p = 0.001), free ascites (p = 0.003), serosal involvement (p = 0.004) and bilateral pleural effusion (p = 0.02) were associated with malignant etiology. Mesenteric thickening/stranding (p = 0.02), mesenteric adenopathy (p < 0.001), necrotic nodes (p = 0.02), splenomegaly (p =  < 0.001) and higher attenuation (> 20HU) of ascitic fluid (p < 0.001) were associated with benign etiology. The presence of mesenteric thickening or stranding (p = 0.01), splenomegaly (p = 0.02), higher ascitic fluid attenuation > 20HU (p =  < 0.01), mesenteric adenopathy (p < 0.01), necrotic nodes (p = 0.03) favored tuberculosis. CT had diagnostic accuracy (79.3, 86.7%), sensitivity (79.2, 74.6%) and specificity (79.4, 97%) for observers 1 and 2, respectively (Kappa 0.713).
CONCLUSION: Contrast-enhanced MDCT has good sensitivity, specificity and accuracy in differentiating benign and malignant etiologies of diffuse peritoneal disease. Multiple common parameters can be used to differentiate between tuberculous peritonitis and peritoneal carcinomatosis.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Diffuse peritoneal disease; Peritoneal carcinomatosis; Peritoneal tuberculosis

Mesh:

Year:  2022        PMID: 35978185     DOI: 10.1007/s00261-022-03641-y

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  5 in total

1.  To identify the features differentiating peritoneal tuberculosis from carcinomatosis on CT scan abdomen taking omental biopsy as a gold standard.

Authors:  Farah Naz; Waseem Akhter Mirza; Nauman Hashmani; Raza Sayani
Journal:  J Pak Med Assoc       Date:  2018-10       Impact factor: 0.781

Review 2.  Diagnostic performance of computed tomography and magnetic resonance imaging for detecting peritoneal metastases: systematic review and meta-analysis.

Authors:  Andrea Laghi; Davide Bellini; Marco Rengo; Fabio Accarpio; Damiano Caruso; Daniele Biacchi; Angelo Di Giorgio; Paolo Sammartino
Journal:  Radiol Med       Date:  2016-09-19       Impact factor: 3.469

3.  Visceral scalloping on abdominal computed tomography due to abdominal tuberculosis.

Authors:  Vishal Sharma; Anmol Bhatia; Sarthak Malik; Navjeet Singh; Surinder S Rana
Journal:  Ther Adv Infect Dis       Date:  2017-02-13

Review 4.  Extrapulmonary tuberculosis.

Authors:  S K Sharma; A Mohan
Journal:  Indian J Med Res       Date:  2004-10       Impact factor: 2.375

5.  Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.

Authors:  G Rubini; C Altini; A Notaristefano; N Merenda; D Rubini; A A Stabile Ianora; A Niccoli Asabella
Journal:  Rev Esp Med Nucl Imagen Mol       Date:  2013-08-13       Impact factor: 1.359

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.